Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)

Line Uhrenholt,Maria E Suarez-Almazor,Robin Christensen,Ellen-Margrethe Hauge,Salome Kristensen,Lene Dreyer,Annette Schlemmer

doi:10.1136/bmjopen-2018-028517

Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)

Line Uhrenholt, Maria E Suarez-Almazor + Show 5 more

Open Access

https://doi.org/10.1136/bmjopen-2018-028517

Copy DOI

Journal: BMJ Open	Publication Date: Jul 1, 2019
Citations: 19	License type: open-access

Affiliation: Frederiksberg Hospital, University of Southern Denmark, Odense University Hospital, Aarhus University Hospital, Aarhus University, Aalborg University Hospital, Aalborg University

#Disease-modifying Antirheumatic Drugs In Patients #Sustained Remission + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionThe The BIOlogical Dose OPTimisation (BIODOPT) trial is a pragmatic, multicentre, randomised controlled, open-label, parallel-group, equivalence study designed to evaluate tapering of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with...

Full Text